| Title |
Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention
|
|---|---|
| Published in |
Headache: The Journal of Head & Face Pain, February 2015
|
| DOI | 10.1111/head.12505_2 |
| Pubmed ID | |
| Authors |
Richard B. Lipton, Stephen D. Silberstein |
| Abstract |
Migraine is a common disabling primary headache disorder that affects an estimated 36 million Americans. Migraine headaches often occur over many years or over an individual's lifetime. By definition, episodic migraine is characterized by headaches that occur on fewer than 15 days per month. According to the recent International Classification of Headache Disorders (third revision) beta diagnostic criteria, chronic migraine is defined as "headaches on at least 15 days per month for at least 3 months, with the features of migraine on at least 8 days per month." However, diagnostic criteria distinguishing episodic from chronic migraine continue to evolve. Persons with episodic migraine can remit, not change, or progress to high-frequency episodic or chronic migraine over time. Chronic migraine is associated with a substantially greater personal and societal burden, more frequent comorbidities, and possibly with persistent and progressive brain abnormalities. Many patients are poorly responsive to, or noncompliant with, conventional preventive therapies. The primary goals of migraine treatment include relieving pain, restoring function, and reducing headache frequency; an additional goal may be preventing progression to chronic migraine. Although all migraineurs require abortive treatment, and all patients with chronic migraine require preventive treatment, there are no definitive guidelines delineating which persons with episodic migraine would benefit from preventive therapy. Five US Food and Drug Association strategies are approved for preventing episodic migraine, but only injections with onabotulinumtoxinA are approved for preventing chronic migraine. Identifying persons who require migraine prophylaxis and selecting and initiating the most appropriate treatment strategy may prevent progression from episodic to chronic migraine and alleviate the pain and suffering associated with frequent migraine. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 146 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 146 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 25 | 17% |
| Student > Master | 19 | 13% |
| Other | 11 | 8% |
| Researcher | 11 | 8% |
| Student > Doctoral Student | 10 | 7% |
| Other | 18 | 12% |
| Unknown | 52 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 28% |
| Nursing and Health Professions | 10 | 7% |
| Biochemistry, Genetics and Molecular Biology | 7 | 5% |
| Agricultural and Biological Sciences | 7 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
| Other | 15 | 10% |
| Unknown | 60 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 140. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2024.
All research outputs
#300,269
of 25,837,817 outputs
Outputs from Headache: The Journal of Head & Face Pain
#61
of 3,542 outputs
Outputs of similar age
#3,585
of 364,160 outputs
Outputs of similar age from Headache: The Journal of Head & Face Pain
#3
of 51 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,542 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,160 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.